Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
AstraZeneca
Fish and Richardson
Colorcon
Chubb
Healthtrust
Boehringer Ingelheim
Argus Health
Cerilliant
Teva

Generated: January 22, 2018

DrugPatentWatch Database Preview

Claims for Patent: 6,335,369

« Back to Dashboard

Summary for Patent: 6,335,369
Title: Treating chronic uremic patients undergoing periodical dialysis
Abstract:Chronic uremic patients undergoing periodical dialysis are treated with carnitine or one of its salts to prevent or treat carnitine deficiency in patients with end stage renal disease. An effective dose of carnitine, preferably L-carnitine fumarate, is administered preferably intravenously into the venous return line after each dialysis session.
Inventor(s): Cavazza; Claudio (Rome, IT)
Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (Rome, IT)
Application Number:09/761,639
Patent Claims: 1. A method of preventing or treating carnitine deficiency in chronic uremic patients undergoing periodic dialysis comprising administering to the patient at the conclusion of dialysis an effective amount of L-carnitine or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein administration is by the intravenous route.

3. The method of claim 1, wherein administration is by the peritoneal route.

4. The method of claim 1, wherein from about 10 to about 20 mg/kg body weight of carnitine, calculated as L-carnitine, is administered into a venous return line at the end of a dialysis session.

5. The method of claim 1, wherein L-carnitine fumarate is administered.

6. A method of preventing or treating carnitine deficiency in chronic uremic patients undergoing periodic dialysis comprising administering to the patient at the conclusion of dialysis an effective amount of L-carnitine fumarate.

7. The method of claim 6, wherein administration is by the intravenous route.

8. The method of claim 6, wherein administration is by the peritoneal route.

9. The method of claim 6, wherein from about 10 to about 20 mg/kg body weight of carnitine, calculated as L-carnitine, is administered into a venous return line at the end of a dialysis session.

10. A method of preventing carnitine deficiency in end stage uremic patients undergoing periodic dialysis over an extended period of time, said method comprising administering to the patent at the conclusion of each dialysis session an effective amount of L-carnitine or a pharmaceutically acceptable salt thereof.

11. The method of claim 10, wherein administration is by the intravenous route.

12. The method of claim 10, wherein administration is by the peritoneal route.

13. The method of claim 10, wherein from about 10 to about 20 mg/kg body weight of carnitine, calculated as L-carnitine, is administered into a venous return line at the end of a dialysis session.

14. The method of claim 10, wherein L-carnitine fumarate is administered.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Queensland Health
Chubb
US Department of Justice
Novartis
QuintilesIMS
Johnson and Johnson
Healthtrust
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot